Silver Book Fact

The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.

Romley, John A., Yuri Sanchez, John R. Penrod, Dana P. Goldman. Survery Results Show That Adults Are Willing To Pay Higher Insurance Premiums For Generous Coverage Of Specialty Drugs. Health Affairs. 2012; 31(4): 683-690

Reference

Title
Survery Results Show That Adults Are Willing To Pay Higher Insurance Premiums For Generous Coverage Of Specialty Drugs
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2012
Authors
Romley, John A., Yuri Sanchez, John R. Penrod, Dana P. Goldman
Volume & Issue
Volume 31, Issue 4
Pages
683-690

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers.…  
  • The 5-year survival rate for all cancers diagnosed from 1996-2003 is 66%, up from 50% in 1975-1977. This improvement reflects progress in early diagnosis and improvements in treatment.  
  • Cancer death rates for all races/ethnicities and both sexes combined decreased by 2.1% per year from 2002-2004, nearly twice the annual decrease of 1.1% per year from 1993-2002.  
  • Investments in cancer care generated $598 billion of additional value for cancer patients diagnosed between 1983 and 1999.  
  • Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient.